Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Center Laboratories, Inc. (4123.TWO)
Taipei, TW
Center Laboratories, Inc. operates as a Taiwanese pharmaceutical enterprise, with its primary focus lying in the manufacturing and distribution of various medical products across Taiwan. Beyond its core drug operations, the firm is heavily invested in the research and development of both small molecule therapeutics and biologics, including proteins and antibodies. Additionally, its extensive portfolio encompasses pharmaceutical CDMO services, medical devices, nutritional health products, agribiotechnology initiatives, advanced stem cell and immune cell therapies, and even strategic ventures in industry investment funds and venture capital. Founded in 1959, Center Laboratories maintains its headquarters in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.65% | -3.27% | -3.39% | -9.32% | +5.78% | -7.57% | +5.08% | -7.01% | -10.91% | +37.42% | +1,861.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-6.3% Q1'26: +23.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+895.5% ★ Q1'26: +247.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+640.6% Q1'26: +24.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+776.5% ★ Q1'26: -4.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+31.4% ★ Q1'26: -0.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.5% Q1'26: +4.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.39× Q1'26: 48.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
|---|---|---|---|---|---|
| Revenue |
6.79B
est: 985.00M (+589.6%)
|
21.65B
est: 25.74B (-15.9%)
|
1.44B
est: 1.99B (-27.6%)
|
717.05M
est: 1.07B (-33.0%)
|
500.11M
est: 610.00M (-18.0%)
|
| EBITDA |
1.09B
est: 197.97M (+448.4%)
|
11.00B
est: 5.17B (+112.6%)
|
381.45M
est: 399.35M (-4.5%)
|
349.11M
est: 215.05M (+62.3%)
|
1.08B
est: 122.60M (+780.3%)
|
| EBIT |
761.99M
est: 136.72M (+457.4%)
|
10.08B
est: 3.57B (+182.1%)
|
207.88M
est: 275.79M (-24.6%)
|
6.08B
est: 148.51M (+3,994.4%)
|
2.70B
est: 84.67M (+3,087.1%)
|
| Net Income |
421.50M
est: 252.58M (+66.9%)
|
6.08B
est: 9.88B (-38.4%)
|
-203.59M
est: 4.89M (-4,262.2%)
|
3.79B
est: 4.51B (-16.1%)
|
1.82B
est: 2.63B (-30.9%)
|
| SGA |
2.34B
est: 555.62M (+320.3%)
|
8.31B
est: 14.52B (-42.8%)
|
502.47M
est: 1.12B (-55.2%)
|
694.23M
est: 603.57M (+15.0%)
|
438.42M
est: 344.09M (+27.4%)
|
| EPS |
0.95
est: 0.36 (+167.0%)
|
10.75
est: 13.92 (-22.7%)
|
-0.35
est: 0.01 (-5,179.1%)
|
6.14
est: 6.36 (-3.5%)
|
2.86
est: 3.70 (-22.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.06% | 45.9K | 0.74% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.05% | 57.7K | 0.42% |
| 3 | State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc) IMID.L | 0.05% | 3.59M | 0.17% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.04% | 133.3K | 0.74% |
| 5 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 143.2K | 0.72% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.04% | 223.7K | 0.55% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.34M | 0.06% |
| 8 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.01% | 121.9K | 0.18% |
| 9 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.01% | 2.97M | 0.18% |
| 10 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 17.7K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Su-Chi Wang | Chief Executive Officer, Chief Investment Officer, Chief Operating Officer & Chairman | 6M | female |
| Jui-Pao Hsu | General President of Pharmaceutical Business | 3M | male |
| Min-Li Lien | Assistant Vice President of Legal Affairs Department | 2M | female |
| Chiun-Yu Lin | Plant Director | 2M | female |
| Ching-Yu Tang | Head of Corporate Governance | 2M | female |
| Hsiu Yueh Lin | Director of Administration Department | — | female |
| An-Ni Mao | Manager of Finance & Accounting Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4123.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
